Clene- Warrants (30/12/2025) Overview
Valuation check: CLNNW's ROE is 159.49%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow159.49%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Clene- Warrants (30/12/2025) (CLNNW) currently reports a ROE of 159.49%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore Clene- Warrants (30/12/2025)'s ROE history and peer comparisons.
Clene- Warrants (30/12/2025)'s ROE of 159.49% is higher than the Healthcare sector average of 20.77%. That is roughly 668.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Clene- Warrants (30/12/2025)'s current 159.49% should be judged against Healthcare norms (sector average: 20.77%) and against CLNNW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 159.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Clene- Warrants (30/12/2025), and consider following CLNNW for alerts when major investors trade the stock.
Clene- Warrants (30/12/2025) is classified in the Healthcare sector. On ROE, it currently shows 159.49% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLNNW with unrelated industries.
